69,986 Shares in NeoGenomics, Inc. (NASDAQ:NEO) Acquired by Semanteon Capital Management LP

Semanteon Capital Management LP bought a new position in NeoGenomics, Inc. (NASDAQ:NEO) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 69,986 shares of the medical research company’s stock, valued at approximately $1,132,000. Semanteon Capital Management LP owned about 0.05% of NeoGenomics as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. AE Wealth Management LLC lifted its holdings in shares of NeoGenomics by 14.4% during the third quarter. AE Wealth Management LLC now owns 36,831 shares of the medical research company’s stock worth $453,000 after buying an additional 4,646 shares during the last quarter. SG Americas Securities LLC acquired a new position in shares of NeoGenomics during the third quarter worth approximately $1,844,000. Brown Advisory Inc. lifted its holdings in shares of NeoGenomics by 25.0% during the third quarter. Brown Advisory Inc. now owns 8,246,202 shares of the medical research company’s stock worth $101,428,000 after buying an additional 1,651,717 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of NeoGenomics by 17.6% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 25,643 shares of the medical research company’s stock worth $315,000 after buying an additional 3,837 shares during the last quarter. Finally, BluePath Capital Management LLC acquired a new position in shares of NeoGenomics during the third quarter worth approximately $30,000. 98.50% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. BTIG Research cut their target price on NeoGenomics from $25.00 to $21.00 and set a “buy” rating for the company in a research note on Friday, December 29th. The Goldman Sachs Group upped their target price on NeoGenomics from $17.00 to $19.00 and gave the company a “buy” rating in a research note on Thursday, February 22nd. William Blair restated an “outperform” rating on shares of NeoGenomics in a research note on Wednesday, February 21st. TD Cowen cut their target price on NeoGenomics from $22.00 to $19.00 and set an “outperform” rating for the company in a research note on Friday, December 29th. Finally, Piper Sandler upped their target price on NeoGenomics from $18.00 to $20.00 and gave the company an “overweight” rating in a research note on Monday, February 26th. Three equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $19.50.

Insider Activity

In other news, General Counsel Alicia C. Olivo sold 2,587 shares of the firm’s stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $14.96, for a total value of $38,701.52. Following the completion of the sale, the general counsel now directly owns 34,866 shares in the company, valued at $521,595.36. The sale was disclosed in a filing with the SEC, which is accessible through this link. 1.30% of the stock is currently owned by corporate insiders.

NeoGenomics Price Performance

NeoGenomics stock traded down $0.18 during mid-day trading on Thursday, hitting $13.85. 791,476 shares of the company were exchanged, compared to its average volume of 893,511. The company has a quick ratio of 5.95, a current ratio of 6.20 and a debt-to-equity ratio of 0.57. The business has a fifty day moving average of $15.04 and a 200 day moving average of $15.88. NeoGenomics, Inc. has a 1-year low of $11.03 and a 1-year high of $21.22. The company has a market capitalization of $1.77 billion, a PE ratio of -19.79 and a beta of 1.10.

NeoGenomics (NASDAQ:NEO) last announced its earnings results on Tuesday, February 20th. The medical research company reported ($0.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.05. NeoGenomics had a negative return on equity of 4.13% and a negative net margin of 14.87%. The company had revenue of $155.55 million during the quarter, compared to analyst estimates of $152.90 million. As a group, sell-side analysts expect that NeoGenomics, Inc. will post -0.2 earnings per share for the current year.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.